ADMP
Closed
Adamis Pharma
0.4901
-0.0150 (-2.97%)
Last Update: 09 Nov 2023 17:30:00
Yesterday: 0.5051
Day's Range: 0.49 - 0.5175
Send
sign up or login to leave a comment!
When Written:
0.1137
Adamis Pharmaceuticals Corporation is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company's product portfolio includes respiratory and allergy medications, injectable and oral products for oncology and immunology, and treatments for central nervous system disorders.
Adamis Pharma is headquartered in San Diego, California, and was founded in 2006. The company has a focus on developing innovative products that address unmet medical needs and improving patient outcomes.
Some of the notable products developed by Adamis Pharma include Symjepi, an epinephrine injection used for the emergency treatment of allergic reactions, and Tempol, a potential treatment for COVID-19.
Adamis Pharma has partnerships with various pharmaceutical companies, including Novartis, Sandoz, and Mylan. The company is publicly traded on the NASDAQ stock exchange under the symbol ADMP.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Adamis Pharma is headquartered in San Diego, California, and was founded in 2006. The company has a focus on developing innovative products that address unmet medical needs and improving patient outcomes.
Some of the notable products developed by Adamis Pharma include Symjepi, an epinephrine injection used for the emergency treatment of allergic reactions, and Tempol, a potential treatment for COVID-19.
Adamis Pharma has partnerships with various pharmaceutical companies, including Novartis, Sandoz, and Mylan. The company is publicly traded on the NASDAQ stock exchange under the symbol ADMP.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








